Tag Archives: Thiothixene

Pharmacotherapy in the Treatment of People With Schizophrenia

The pharmacological agents most primarily associated with treatment of schizophrenia are grouped in a large and heterogeneous family, the antipsychotics. Recently, this family has been subdivided into the typicals, or neuroleptics, and the atypicals (see Tables Selected Typical Antipsychotic Drugs and Their Characteristics and Atypical Antipsychotics: Relative Potencies and Side Effects). The neuroleptics are so… Read More »

Adjunctive Pharmacotherapy and Related Issues

Managing antipsychotic side effects. Antipsychotic drugs produce problematic side effects in many individuals (see Table Side Effects of Typical Antipsychotic Drugs). A major category of side effects results from neurotransmitter dysregulation of the extra-pyramidal motor system. It is thought that these side effects are the result of an imbalance of dopaminergic and acetylcholinergic activity in… Read More »

Pharmacological treatment for schizophrenia

Pharmacological treatments are an essential component of a comprehensive approach to the treatment of schizophrenia. Rational pharmacotherapies can contribute greatly to symptom relief and to a broader psychosocial recovery for affected individuals. However, antipsychotic drugs do not cure schizophrenia. Moreover, if not used judiciously, drug therapies can create significant financial, side-effect, and medical morbidity burdens… Read More »

Treatment for Schizophrenia: Antipsychotic Drugs

Modern drug treatment for schizophrenia dates to the early 1950s, when Deniker and Delay reported the antipsychotic effects of chlorpromazine (). Chlorpromazine was introduced in the United States in 1954, followed over the next three decades by several drugs, including fluphenazine, haloperidol, perphenazine, and thioridazine, with similar therapeutic effects. All of these so-called first-generation antipsychotics… Read More »

Antipsychotics For The Treatment Of Schizophrenia

Following the Anatomical Therapeutic Chemical (ATC) classification system by WHO Collaborating Centre for Drug Statistics Methodology), antipsychotics (ATC N05A) are classified as: • N05AA Phenothiazines with aliphatic side-chain: Chlorpromazine, Levomepromazine, Promazine, Triflupromazine, Cyamemazine, Chlorproethazine • N05AB Phenothiazines with piperazine structure: Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine • N05AC Phenothiazines with piperidine… Read More »

Typical Antipsychotics For The Treatment Of Schizophrenia

Lithium • Lithium and lithium salts (especially carbonate or citrate) were the focus of research in depression topic in the 1930’s. Lithium carbonate was launched in 1939 by Solvay for the treatment of depression and schizophrenia, and in 2002 Glaxo launched it for the treatment of mania • For many years, the effect of lithium… Read More »

Drugs in Treatment of Schizophrenia

  The introduction of chlorpromazine (Thorazine), the first of the antipsychotic drugs (also known as neuroleptics), in 1952 revolutionized the treatment of schizophrenia. Since then, these drugs have become the mainstay of treatment for people with schizophrenia. Before these drugs were discovered, many who suffered from this illness spent most of their lives in hospitals,… Read More »

Schizophrenia, Psychotic Disorders, and Antipsychotics

The primary indication for use of antipsychotics is the presence of psychosis in a number of conditions, including schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder (which maybe present in a number of personality disorders), mood disorders with psychotic features, or psychotic disturbance secondary to an underlying medical condition or substance use disorders, resulting from… Read More »


Quetiapine Pharmacology Quetiapine is an atypical antipsychotic with a half-life of two to three hours. It has high affinity for 5-HT2A receptors and weak affinity for dopamine, muscarinic, and adrenergic receptors. Typical antipsychotic doses are 150 to 800 mg daily. Sleep Efficacy There are no randomized controlled trials in primary insomnia. Quetiapine 25 or 100… Read More »

Mood Stabilizing Medications in the Treatment of Psychotic Disorders

Mood Stabilizing Medications in the Treatment of Psychotic Disorders of Children and Adolescents, Other Treatments, and Alternative Treatments For a variety of reasons, other medications are added frequently to the psychopharmacological treatment of chronic psychotic conditions in children and adolescents. Among these, mood stabilizers (valproate, lithium, lamotrigene, and others) play a significant role in the… Read More »